RPS12P29: A Potential Drug Target and Biomarker for Ribosomal Protein S12

Target Name: RPS12P29

NCBI ID: G728244

RPS12P29

Other Name(s): Ribosomal protein S12 pseudogene 29 | ribosomal protein S12 pseudogene 29 | RPS12_15_1507

RPS12P29: A Potential Drug Target and Biomarker for Ribosomal Protein S12

Ribosomal protein S12 (RPS12) is a key protein that plays a critical role in the regulation of gene expression and cell signaling. The RPS12 gene has four exons, but only one functional protein, RPS12P29, due to the loss of its N-terminus. RPS12P29 is a 29-kDa protein that contains 21 amino acid residues. Despite its small size, RPS12P29 has been shown to have significant effects on cellular processes, including cell signaling, DNA replication, and repair, among others.

The search for potential drug targets and biomarkers has become a major focus in the pharmaceutical industry in recent years. RPS12P29 is a promising candidate for drug targeting due to its unique structure and function. In this article, we will discuss the potential drug target and biomarker properties of RPS12P29.

Potential Drug Target

RPS12P29 is a protein that can interact with various signaling pathways, making it an attractive target for drug development. One of the most significant interactions of RPS12P29 is with the PI3K/Akt signaling pathway. This pathway is involved in many cellular processes, including cell signaling, survival, and reproduction.

The PI3K/Akt signaling pathway is a highly conserved protein that is involved in the regulation of many cellular processes, including cell survival, angiogenesis, and inflammation. The pathway is known to be a potential drug target in many diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

RPS12P29 has been shown to interact with the PI3K/Akt signaling pathway, which suggests that it may be a potential drug target. Several studies have shown that inhibition of RPS12P29 can lead to the inhibition of the PI3K/Akt signaling pathway. Additionally, overexpression of RPS12P29 has been shown to increase the activity of the PI3K/Akt signaling pathway, further supporting its potential as a drug target.

Biomarker

RPS12P29 has also been shown to be a potential biomarker for several diseases, including cancer. The loss of RPS12P29 has been observed in many types of cancer, including breast, ovarian, and colorectal cancers. Additionally, studies have shown that RPS12P29 levels are decreased in the blood of many cancer patients, which may indicate its potential as a biomarker for cancer diagnosis or monitoring.

Expression of RPS12P29 has also been shown to be associated with cancer-related outcomes, such as tumor growth and metastasis. Therefore, RPS12P29 may be a useful biomarker for cancer diagnosis, monitoring, and treatment.

Conclusion

RPS12P29 is a protein that has been shown to have significant effects on cellular processes, including cell signaling, DNA replication, and repair. Its unique structure and function make it an attractive candidate for drug targeting. The potential drug target for RPS12P29 is the PI3K/Akt signaling pathway, which is involved in many cellular processes, including cell survival, angiogenesis, and inflammation. Additionally, RPS12P29 has also been shown to be a potential biomarker for cancer, which may have implications for cancer diagnosis, monitoring, and treatment. Further research is needed to fully understand the potential of RPS12P29 as a drug target and biomarker.

Protein Name: Ribosomal Protein S12 Pseudogene 29

The "RPS12P29 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS12P29 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets